Press Release: Novartis to file for new -2-

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] Clinicaltrials.gov. (2018). RAINBOW Study: RAnibizumab Compared

With Laser Therapy for the Treatment of INfants BOrn Prematurely With

Retinopathy of Prematurity - Study Results - ClinicalTrials.gov.

[online] Available at:

https://clinicaltrials.gov/ct2/show/results/NCT02375971 [Accessed 30

Aug. 2018].

[2] Mintz-Hittner, H., Kennedy, K. and Chuang, A. (2011). Efficacy of

Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. New

England Journal of Medicine, 364(7), pp.603-615.

[3] Blencowe, H., Lawn, J., Vazquez, T., Fielder, A. and Gilbert, C.

(2013). Preterm-associated visual impairment and estimates of

retinopathy of prematurity at regional and global levels for 2010.

Nature, 74(s1), pp.35-49.

[4] Nei.nih.gov. (2018). Facts About Retinopathy of Prematurity (ROP)

| National Eye Institute. [online] Available at:

https://nei.nih.gov/health/rop/rop [Accessed 30 Aug. 2018].

[5] Medicines.org.uk. (2018). Lucentis 10 mg/ml solution for

injection - Summary of Product Characteristics (SmPC) - (eMC). [online]

Available at: https://www.medicines.org.uk/emc/product/307/smpc

[Accessed 30 Aug. 2018].

[6] Keshet, E. (2003). Preventing pathological regression of blood

vessels. Journal of Clinical Investigation, 112(1), pp.27-29.

[7] Moorfields.nhs.uk. (2018). Anatomy of the eye - Moorfields Eye

Hospital. [online] Available at:

https://www.moorfields.nhs.uk/content/anatomy-eye [Accessed 30 Aug.

2018].

###

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Amy Wolf

Novartis Global Media Relations Global Head Communications, Ophthalmology

+41 61 324 7999 (direct) +41 61 696 5894 (direct)

+41 79 593 4202 (mobile) +41 79 576 0723 (mobile)

eric.althoff@novartis.com amy.wolf@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2217264/866356.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

September 22, 2018 08:41 ET (12:41 GMT)